Trends in immunosuppression after pancreas transplantation: What is in the pipeline?

Current Opinion in Organ Transplantation

Volumn 18, Issue 1, 2013, Pages 76-82

  Kimelman, Michael ^a   Brandacher, Gerald ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody induction; immunosuppression; maintenance therapy; pancreas transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

BACTERIAL INFECTION; BK VIRUS INFECTION; BK VIRUS NEPHROPATHY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; LENGTH OF STAY; LOW DRUG DOSE; LOW RISK POPULATION; LUNG EDEMA; MICROCHIMERISM; MONOTHERAPY; PANCREAS TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STEROID THERAPY; T CELL DEPLETION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS;

EID: 84872971480     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835c6eda     Document Type: Review

References (51)

1. Gruessner AC. 2011 Update on pancreas transplantation: comprehensive trend analysis of 25 000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011; 8:6-16.
2. Rangel EB. The metabolic and toxicological considerations for immunosup-pressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol 2012; 8:1531-1548.
3. Waki K, Terasaki PI, Kadowaki T. Long-term pancreas allograft survival in simultaneous pancreas-kidney transplantation by era: UNOS registry analysis. Diabetes Care 2010; 33:1789-1791.
4. Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant 2008; 13:79-84.
5. Heilman RL, Mazur MJ, Reddy KS. Immunosuppression in simultaneous pancreas-kidney transplantation. Drugs 2010; 70:793-804.
6. White SA, Shaw JA, Sutherland DER. Pancreas transplantation. Lancet 2009; 373:1808-1817.
7. Andreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7:1359-1375.
8. Han DJ, Sutherland DE. Pancreas transplantation. Gut Liver 2010; 4:450-465.
9. Gruessner AC, Sutherland DE, Gruessner RW. Pancreas transplantation in the United States: a review. Curr Opin Organ Transplant 2010; 15:93-101.
10. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction: long-term results. Am J Transplant 2006; 6:331-339.
11. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88:810-819.
12. Uemura T, Ramprasad V, Matsushima K, et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation 2011; 92:678-685.
13. Reddy KS, Devarapalli Y, Mazur M, et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transplant Proc 2010; 42:2006-2008.
14. Boggi U, Vistoli F, Egidi FM, et al. Transplantation of the pancreas. Curr Diab Rep 2012; 12:568-579.
15. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 2009; 87:125-132.
16. Bazerbachi F, Selzner M, Boehnert MU, et al. Thymoglobulin versus basilix-imab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 2011; 92:1039-1043.
17. Zhang R, Florman S, Devidoss S, et al. A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am J Transplant 2007; 7:1815-1821.
18. Zhang R, Florman S, Devidoss S, et al. The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin Transplant 2007; 21:583-589.
19. Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008; 8:1702-1710.
20. Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multi-center study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc 2005; 37: 3531-3534.
21. Becker LE, Nogueira VA, Abensur H, et al. No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis. Transplant Proc 2006; 38:1933-1936.
22. Rasaiah SB, Light JA, Sasaki TM, Currier CB. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin Transplant 2000; 14 (4 Pt 2):409-412.
23. Bruce DS, Sollinger HW, Humar A, et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001; 72:1637-1643.
24. Lo A, Stratta RJ, Alloway RR, et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int 2001; 14:396-404.
25. Chow FYF, Polkinghorne K, Saunder A, et al. Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology (Carlton) 2003; 8:212-216.
26. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calci-neurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
27. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564-577.
28. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-1510.
29. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transplant Int 2009; 22:61-68.
30. Mineo D, Sageshima J, Burke GW, Ricordi C. Minimization and withdrawal of steroids in pancreas and islet transplantation. Transplant Int 2009; 22: 20-37.
31. Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymo-cyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000; 69:1505-1508.
32. Aoun M, Eschewege P, Hamoudi Y, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant 2007; 22:899-905.
33. Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosup-pression. Transplantation 2006; 82:389-392.
34. Vessal G, Wiland AM, Philosophe B, et al. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin Transplant 2007; 21:491-497.
35. Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007; 83:1324-1329.
36. Gruessner RWG, Kandaswamy R, Humar A, et al. Calcineurin inhibitor-and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005; 79:1184-1189.
37. Muthusamy ASR, Vaidya AC, Sinha S, et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008; 8:2126-2131.
38. Rajab A, Pelletier RP, Ferguson RM, et al. Steroid-free maintenance immu-nosuppression with rapamune and low-dose neoral in pancreas transplant recipients. Transplantation 2007; 84:1131-1137.
39. Tanchanco R, Krishnamurthi V, Winans C, et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation. Transplant Proc 2008; 40:1551-1554.
40. Malheiro J, Martins L, Fonseca I, et al. Steroid withdrawal in simultaneous pancreas-kidney transplantation: a 7-year report. Transplant Proc 2009; 41:909-912.
41. Ciancio G, Sageshima J, Chen L, et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. Am J Transplant 2012; doi: 10.1111/j.1600-6143.2012.04235.x
42. Girman P, Lipar K, Koznarova R, et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. Transplant Proc 2010; 42:1999-2002.
43. Knight RJ, Podder H, Kerman RH, et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation 2010; 89:727-732.
44. Kirchner VA, Suszynski TM, Radosevich DM, et al. Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation. Transplant Proc 2010; 42:2003-2005.
45. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one-and two-year outcomes. Transplantation 2006; 82:1621-1624.
46. Delis S, Burke GW 3rd, Ciancio G. Bone marrow-induced tolerance inthe era of pancreas and islets transplantation. Pancreas 2006; 32:1-8.
47. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11:1444-1455.
48. Wojciechowski D, Vincenti F. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant 2011; 16:614-619.
49. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
50. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
51. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10:2154-2160.